Spectris acquires Concept Life Sciences for £163m
Concept represents a new, high-growth area for Spectris, and will become a separate operating company within its Materials Analysis segment where it has strong synergies with the activities
Teva Pharmaceutical has announced the US Food and Drug Administration (FDA) approval for Ponlimsi (denosumab-adet) as a biosimilar to Prolia, alongside the acceptance of its biosimilar candidate applications for Xolair (omalizumab) by both the agency and the European Medicines Agency (EMA).
GEP-NET is a form of cancer that affects the pancreas or gastrointestinal tract. The approval is for adult patients with somatostatin receptor-positive GEP-NETs and it covers conditions like foregut, midgut,
This designation is for treating patients diagnosed with HER2-positive metastatic breast cancer (MBC) that has progressed during or after at least two HER2-targeting treatment regimens for locally advanced
The randomized, double-blind REFLECTIONS B3281006 clinical trial assessed the efficacy, safety, pharmacokinetics and immunogenicity of PF-05280586 in comparison to rituximab. It demonstrated equivalence of the biosimilar candidate in